CC
DXCM icon

Centiva Capital’s DexCom DXCM Stock Holding History

Centiva Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,036
Closed -$2.27M – 1283
2025
Q2 		$2.27M Sell
26,036
-2,151
-8% -$169K 0.04% 309
2025
Q1 		$1.92M Buy
28,187
+18,710
+197% +$1.53M 0.06% 196
2024
Q4 		$737K Sell
9,477
-13,650
-59% -$1.01M 0.02% 631
2024
Q3 		$1.55M Buy
23,127
+19,867
+609% +$1.63M 0.03% 586
2024
Q2 		$370K Sell
3,260
-845
-21% -$107K 0.01% 1348
2024
Q1 		$569K Buy
+4,105
New +$516K 0.01% 923
2023
Q4 		– Sell
-16,830
Closed -$1.57M – 1904
2023
Q3 		$1.57M Buy
16,830
+677
+4% +$76.3K 0.03% 463
2023
Q2 		$2.08M Buy
+16,153
New +$1.95M 0.05% 371
2023
Q1 		– Sell
-17,104
Closed -$1.94M – 1599
2022
Q4 		$1.94M Buy
+17,104
New +$1.88M 0.05% 370
2022
Q2 		– Sell
-624
Closed -$80K – 1759
2022
Q1 		$80K Sell
624
-9,252
-94% -$1.01M ﹤0.01% 1396
2021
Q4 		$1.33M Buy
+9,876
New +$1.42M 0.03% 499

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Centiva Capital's DXCM Position: Q3 2025 in Review

Centiva Capital sold out of DexCom (DXCM) in Q3 2025, closing a stake of 26,036 shares — an estimated $2.27M sold.

Centiva Capital first reported a position in DXCM in Q4 2021 and held it in 11 quarters. The position peaked at $2.27M in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Centiva Capital reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 26,036 DexCom shares in Q3 2025, an estimated $2.27M.
  • Centiva Capital first reported a position in DexCom in Q4 2021 and held it in 11 quarters.
  • Centiva Capital's DexCom position peaked at $2.27M in Q2 2025.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.